de Lartigue J
Drugs Today (Barc). 2012 Oct;48(10):655-60. doi: 10.1358/dot.2012.48.10.1885878.
T-cell neoplasms, such as adult T-cell leukemia/lymphoma (ATL) and peripheral T-cell lymphoma, are particularly aggressive and, despite novel combination chemotherapy regimens, still have extremely poor prognoses. As such, there is an unmet medical need for novel therapies and the anti-chemokine CCR4 receptor antibody mogamulizumab (KW-0761) may offer such an option for the treatment of ATL. Mogamulizumab is a humanized antibody, with a defucosylated Fc region, which enhances antibody-dependent cellular cytotoxicity. As a result, mogamulizumab demonstrates potent antitumor activity at much lower doses than other therapeutic monoclonal antibodies. Clinical testing indicates that mogamulizumab is effective and well tolerated, with a predictable pharmacokinetic profile in patients with relapsed/refractory ATL. This drug was recently granted regulatory approval in Japan for this indication and continues to be evaluated in clinical trials in both the U.S. and Europe.
T细胞肿瘤，如成人T细胞白血病/淋巴瘤（ATL）和外周T细胞淋巴瘤，具有特别强的侵袭性，尽管有新的联合化疗方案，但预后仍然极差。因此，对于新型疗法存在未满足的医疗需求，抗趋化因子CCR4受体抗体莫加莫珠单抗（KW-0761）可能为ATL的治疗提供这样一种选择。莫加莫珠单抗是一种人源化抗体，具有去岩藻糖基化的Fc区域，可增强抗体依赖性细胞毒性。因此，莫加莫珠单抗在比其他治疗性单克隆抗体低得多的剂量下就能表现出强大的抗肿瘤活性。临床试验表明，莫加莫珠单抗有效且耐受性良好，在复发/难治性ATL患者中具有可预测的药代动力学特征。该药物最近在日本获得了这一适应症的监管批准，并且在美国和欧洲的临床试验中仍在继续评估。
